LABU News and Press, Direxion Daily S&P Biotech Bull 3X Shares From 07/14/22

Resubmission of BLA for DAXI for glabellar lines achieved, PDUFA date established for September 8, 2022. The global Botulinum Toxin market is expected to reach $7.71 billion by 2027. Since launch of the RHA Collection, sales reached $100 million, with first-quarter revenue totalin...

Proof of concept has been established in using Barzolvolimab in treating Chronic spontaneous urticaria and Chronic inducible urticaria patients in phase 1b studies. One phase 2 study with Barzolvolimab treating Chronic spontaneous urticaria patients has been initiated with second phas...

RGNX is proceeding towards becoming a pillar of the gene therapy space for ocular diseases. However, it will need time to get there. The company is adequately funded for the journey. REGENXBIO Inc. ( RGNX ) is a developer of genetic treatments for eye diseases. Data ...

Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in Q1 of 2024. If the primary endpoint of the phase 3 NAVIGATE study is met, ability to advance Belapectin towards other indications such ...

Biogen is beginning to have a trend change. Biogen is at the bottom of a trading range that goes back 10 years. Now may be a good time to initiate a position with earnings coming soon. As I look at price charts at the end of the week for potential buys or shorts I notice...

Gainers: Direxion Daily S&P Biotech Bull 3x Shares ETF ( LABU ) +45% . Axs 2X Innovation ETF ( TARK ) +35% . Direxion Daily Homebuilders & Supplies Bull 3x Shares ETF ( NAIL ) +27% . Direxion Daily Dow Jones Internet Bull 3X Shares ( W...

DexCom has a leading position in a huge and growing market of continuous glucose monitoring. Medical technology is a growing space, with powerful demographic forces leading to outsized long-term growth. The stock has pulled back to an entry point that has it a strong buy for a 5+ ...

Ublituximab used to be TGTX's second asset and a very large potential icing on the cake for the company. After umbralisib went down, ubli has become its lifeline. While data is consistently good, one wonders what the FDA asked for with the new data that led to a delay. F...

Starting with September 2021, LABU had a record sequence of nine consecutive months with negative returns. During the biotech downtrend from September 2021 to April 2022, LABD has returned 207%. During the biotech uptrend from April 2020 to January 2021, in only ten months, LABU h...

Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as e...